N/A N=160 Effect of Intraoperative Crystalloid Volume on Postoperative Vomiting
Postoperative Vomiting
Primary: Postoperative Vomiting — 11; 9; 66; 68 participants — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=300 Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
Phase 2 N=30 Topical Capsaicin for Cyclical Vomiting
Cyclical Vomiting
Primary: Nausea Visual Analog Scale — 41; 61 mm
N/A N=208 Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children
Postoperative Nausea and Vomiting
Primary: Number of Patients With Nausea, Emesis, Severe Nausea, Severe Emesis and Number Receiving Rescue Antiemetics in the Post-Anesthetic Care Unit (PACU) — 60; 13; 8; 2…
Phase 2 N=150 Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome
Primary: The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period. — 0.69; 1.43; 1.33; 1.48 event — p=0.7024
Phase 2 N=41 Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Acute Myeloid Leukemia
Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants
Phase 3 N=321 BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
Gastroenteritis · Gastritis
Primary: Treatment Success From 30 Minutes Through 24 Hours After First Dose of Study Medication - ITT Population — 126; 70; 12; 5 Participants — p=0.0406
Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
Phase 2 N=393 Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
Diabetes Mellitus · Diabetes Mellitus Complications · Gastroparesis
Primary: Change From Baseline to Week 12 in Weekly Vomiting Episodes — 5.7; 7.7; 6.9; 4.8 vomiting episodes per week — p=0.36
N/A N=49 Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
N/A N=64 Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Colorectal Cancer · Nausea · Vomiting
Primary: Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy — 64; 34; 100 percentage of participants — p=.05
Phase 2 N=64 Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
Nausea and Vomiting
Primary: Vomiting at 0 to 120 Min. — 1; 4 number of participants exp vomiting
Phase 2 N=30 Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
Phase 2 N=126 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
Gastroparesis
Primary: Number of Participants With Improvement in Nausea — 29; 25 participants — p=0.43
N/A N=80 Inhalation Intervention for Nausea in the Emergency Department
Nausea · Vomiting
Primary: Nausea Verbal Numerical Rating Scale (0-10) at 10 Minutes Post Intervention — 3; 6 VNRS
Phase 4 N=289 The Montefiore Metoclopramide Study
Nausea · Extrapyramidal Symptoms
Primary: Nausea Scale — 0; 0; 0; 0 units on a scale
Phase 3 N=30 Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
Advanced Cancer
Primary: Mean Nausea Scores — 1; 9 units on a scale
Phase 4 N=122 Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department
Nausea
Primary: Nausea 100 mm Visual Analogue Scale (VAS) — 23; 19; 42 units on a scale
N/A N=161 Acupuncture and Nausea/Vomiting in Pediatric Patients
Postoperative Vomiting and Nausea
Primary: Postoperative Nausea and Vomiting — 26; 6; 37; 31 Participants
N/A N=9 Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants
Phase 2 N=165 Norovirus Challenge Study
Norovirus Infections
Primary: Number of Participants Who Experienced Norovirus Gastroenteritis (NVG) — 34; 37 Participants
Phase 4 N=72 Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide
Pregnancy · Cesarean Section · Aspiration
Primary: Change in Gastric Volume (mL) — -1; -2; 0; 1 Milliliters — p=.001
N/A N=47 Auricular Neurostimulation for Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome · Abdominal Migraine
Primary: Rhodes Index of Nausea, Vomiting & Retching (INVR) — 3.25; 5.80; 10.43; 0.75 score on a scale
N/A N=51 EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
Nausea
Primary: Time to Nausea Reduction by 50% by Visual Analog Scale. — 4.3; 3.5 Minutes
Phase 2 N=52 Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
Intestinal Obstruction
Primary: Percentage of Responders Before or at Day 7 — 88.2; 25.7; 46.2 percentage of responders — p=0.0055
Phase 3 N=317 Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Breast Carcinoma
Primary: Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or…